The Macular Minute Episode 9
with Rossella Anzidei
Treatment Pathways for EYLEA® (aflibercept) 8 mg
In this 3-minute episode, we are joined by Rossella Anzidei, a Consultant Ophthalmologist at University Hospitals Leicester NHS Trust, to discuss treatment pathways for EYLEA 8 mg.
This promotional podcast series has been organised and funded by Bayer and is for UK healthcare professionals only.
Prescribing information for EYLEA® (aflibercept) 8 mg can be found here.
Prescribing information for EYLEA® (aflibercept) 2 mg can be found here.
Rossella Anzidei
Ms Rossella Anzidei, FRCOphth, is a Consultant Ophthalmologist in University Hospitals of Leicester, specialised in Medical Retina conditions, including age-related macular degeneration, diabetic retinopathy and retinal vein occlusion. Ms Anzidei has been Principal Investigator of randomized controlled trials and she is lecturer for the Medical School in Leicester. Ms Anzidei contributed to the expansion of the Macula Service and she received the 'Caring at its Best' Award from the University Hospitals of Leicester for the high-quality care and the improvement of NHS services.
Speaker Disclosures
Speaker and travel grants: AbbVie, Bayer and Novartis
References
- EYLEA® 40 mg/mL Summary of Product Characteristics.
- EYLEA® 114.3 mg/mL Summary of Product Characteristics.
PP-EYL-GB-2549 | December 2024